In a patient with a pathogen resistant to ceftazidime, aztreonam, imipenem, and meropenem but intermittently susceptible to colistin, what antimicrobial therapy should be administered?

Treatment Recommendation for Multidrug-Resistant Pathogen

For a pathogen resistant to ceftazidime, aztreonam, imipenem, and meropenem with only intermittent susceptibility to colistin, prioritize newer β-lactam/β-lactamase inhibitor combinations—specifically ceftazidime-avibactam, ceftolozane-tazobactam, or imipenem-cilastatin-relebactam—as first-line therapy if susceptibility testing confirms activity. If these agents are unavailable or the organism is resistant, use colistin-based combination therapy rather than colistin monotherapy, combining colistin with a carbapenem (meropenem preferred) at extended infusion despite in vitro resistance 1.

Algorithmic Approach to Treatment Selection

Step 1: Identify the Pathogen and Resistance Mechanism

This resistance pattern suggests either difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA) or carbapenem-resistant Enterobacterales (CRE). The key distinction is whether metallo-β-lactamase (MBL) is present, as this determines optimal therapy 1.

• If DTR-PA suspected: Obtain susceptibility testing for ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam 1
• If CRE suspected: Test for carbapenemase type (KPC, OXA-48, NDM) and obtain susceptibilities to newer agents 1

Step 2: First-Line Therapy Selection

For DTR-PA (non-MBL producers):

• Ceftolozane-tazobactam: 3 g IV q8h (for pneumonia) or 1.5 g IV q8h (other infections) 1, 2
• Ceftazidime-avibactam: 2.5 g IV q8h 1
• Imipenem-cilastatin-relebactam: 1.25 g IV q6h 1

For CRE (non-MBL producers):

• Ceftazidime-avibactam: 2.5 g IV q8h 1
• Meropenem-vaborbactam: 4 g IV q8h 1
• Imipenem-cilastatin-relebactam: 1.25 g IV q6h 1

For MBL producers (NDM, VIM, IMP):

• Ceftazidime-avibactam PLUS aztreonam: This combination is critical as avibactam protects aztreonam from other β-lactamases while aztreonam remains active against MBL producers 3, 4, 5
• Cefiderocol: May be considered as alternative 6, 2

Step 3: Colistin-Based Therapy (When Newer Agents Unavailable or Resistant)

Given the "intermittent susceptibility" to colistin—which suggests borderline MIC values or heteroresistance—colistin should NOT be used as monotherapy 1.

Recommended colistin combination regimen:

• Colistin: Loading dose 5 mg/kg (CBA) IV × 1, then maintenance 2.5 mg × (1.5 × CrCl + 30) IV q12h 1
• PLUS Meropenem: 1 g IV q8h by extended infusion (3-hour infusion) 1
• Alternative combination partner: Tigecycline 100 mg IV loading, then 50 mg IV q12h 1

The rationale for adding a carbapenem despite resistance is that combination therapy with colistin plus meropenem showed potential mortality benefit even when the carbapenem lacked in vitro activity, likely through synergistic mechanisms 1.

Critical Dosing Considerations

Colistin Dosing (from FDA label and guidelines):

• Loading dose: 5 mg/kg CBA (colistin base activity) IV × 1 dose 7
• Maintenance: 2.5 mg × (1.5 × CrCl + 30) IV q12h 1, 7
• Note: 1 million IU colistin methanesulfonate ≈ 33 mg CBA 1

Renal Function Monitoring:

Colistin carries significant nephrotoxicity risk—acute kidney injury is associated with clinical failure and mortality 1. Monitor renal function closely throughout therapy (strong recommendation) 1.

Common Pitfalls and How to Avoid Them

Pitfall 1: Using Colistin Monotherapy

The evidence shows controversy regarding combination versus monotherapy, but expert consensus favors combination therapy for severe infections 1. Never use colistin alone when dealing with intermittent susceptibility.

Pitfall 2: Inadequate Colistin Loading Dose

Many clinicians omit the loading dose, resulting in subtherapeutic levels for the first 24-48 hours. Always use the 5 mg/kg loading dose 1.

Pitfall 3: Not Testing for Newer Agents

Data shows 80% of imipenem-resistant P. aeruginosa in Taiwan remain susceptible to amikacin, ceftazidime-avibactam, and ceftolozane-tazobactam 1. Always obtain susceptibility testing for newer β-lactam/β-lactamase inhibitors 1.

Pitfall 4: Ignoring Metallo-β-Lactamase Status

If MBL is present, ceftazidime-avibactam and ceftolozane-tazobactam will fail. The combination of ceftazidime-avibactam PLUS aztreonam is specifically designed for MBL producers 3, 4, 5.

Treatment Duration

• Bloodstream infections: 10-14 days 1
• Pneumonia (HAP/VAP): 10-14 days 1
• Complicated UTI: 5-10 days 1
• Complicated intra-abdominal infections: 5-10 days 1

Duration should be individualized based on source control, clinical response, and underlying comorbidities 1.

When Combination Therapy is Mandatory

For severe infections or unstable hemodynamics, combination therapy is strongly preferred over monotherapy 8. The 2022 guidelines specifically recommend considering combination therapy for clinically unstable patients with carbapenem-resistant infections 1.